Sunnybrook’s Odette Cancer Centre, a world-class cancer center in Toronto, Ontario, Canada, joins BriaCell’s pivotal Phase 3 clinical trial in metastatic breast cancer BriaCell Phase 3 trial ...
Arrangement with FUJIFILM Biotechnologies California provides manufacturing capacity for the remainder of BriaCell’s pivotal Phase 3 study and commercial scalability potential Bria-IMT is currently...
Charles River Associates (CRA) to evaluate epidemiology, pricing, prescriber dynamics, and market access potential for Bria-IMT in metastatic breast cancer in the US Kaleio to support brand strategies...
Agreement supports potential commercial readiness for Bria-IMT using Uneedle’s proprietary microneedle technology for intradermal administration Technology is currently used in BriaCell’s pivotal...
PHILADELPHIA & VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
Final Bria-IMT™ Phase 2 data show 55% >1 year and 27% >2-year survival in heavily pre-treated metastatic breast cancer (MBC) patients treated with Bria-IMT regimen selected for Phase 3 TWiST...
PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
Independent DSMB has identified no safety concerns, to date, and recommends continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitor Sixth consecutive positive...
Final Phase 2 Bria-IMT median overall survival (OS) is 16.6 months (with Phase 3 formulation) Positive Quality of Life (QOL) data from the ongoing Phase 3 study in heavily pre-treated metastatic...
BriaCell expands push in women’s health, building on Phase 2 success in advanced metastatic breast cancer Bria-OVA+, BriaCell’s next generation personalized immunotherapy candidate for ovarian...